GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Other Operating Expense

Kaken Pharmaceutical Co (TSE:4521) Other Operating Expense : 円16,479 Mil (TTM As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Other Operating Expense?

Kaken Pharmaceutical Co's Other Operating Expense for the three months ended in Dec. 2023 was 円4,015 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was 円16,479 Mil.

Kaken Pharmaceutical Co's quarterly Other Operating Expense increased from Jun. 2023 (円4,161 Mil) to Sep. 2023 (円4,306 Mil) but then declined from Sep. 2023 (円4,306 Mil) to Dec. 2023 (円4,015 Mil).

Kaken Pharmaceutical Co's annual Other Operating Expense declined from Mar. 2022 (円16,088 Mil) to Mar. 2023 (円15,764 Mil) but then increased from Mar. 2023 (円15,764 Mil) to Mar. 2024 (円16,479 Mil).


Kaken Pharmaceutical Co Other Operating Expense Historical Data

The historical data trend for Kaken Pharmaceutical Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Other Operating Expense Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17,548.00 16,379.00 16,088.00 15,764.00 16,479.00

Kaken Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,908.00 4,161.00 4,306.00 4,015.00 3,997.00

Kaken Pharmaceutical Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円16,479 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaken Pharmaceutical Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines